secukinumab
Sign in to saveAlso known as AIN457, AIN-457, Cosentyx
Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, psoriatic arthritis, and hidradenitis suppurativa. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.
In the Vinony graph
Vinony's link graph records 388 inbound references to secukinumab, and connects out to monoclonal antibody, Interleukin 2 and subcutaneous injection.
It sits within the topics Chemicals that do not have a ChemSpider ID assigned, Disease-modifying antirheumatic drugs and Drugboxes which contain changes to verified fields.
Vinony links it to 22 Wikipedia language editions.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 464388281
- Drug.type
- mab
- Drug.image
- Autoinjector with Cosentyx by Novartis (Secukinumab)-0522.jpg
- Drug.caption
- Autoinjector with Cosentyx by Novartis (secukinumab)
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- IL17A
- Drug.tradename
- Cosentyx
- Drug.MedlinePlus
- a615011
- Drug.DailyMedID
- Secukinumab
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- Subcutaneous, intravenous
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AC10
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
via Wikipedia infobox
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Antibody
- First approval
- 2015
- Admin. routes
- parenteral
- Indications
- ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis
via ChEMBL · EBI
Research
2,939 papers- Bimekizumab versus Secukinumab in Plaque Psoriasis.The New England journal of medicine · 2021
- Secukinumab in plaque psoriasis--results of two phase 3 trials.The New England journal of medicine · 2014
- Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.Lancet (London, England) · 2023
- Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.The New England journal of medicine · 2015
- Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.Annals of the rheumatic diseases · 2021
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 8 more facts
- side effect
- eczema
- chemical formula
- C₆₅₈₄H₁₀₁₃₄N₁₇₅₄O₂₀₄₂S₄₄
- World Health Organisation international non-proprietary name
- secukinumab
- defined daily dose
- 10
- medical condition treated
- ankylosing spondylitis
- Commons category
- Secukinumab
- has characteristic
- biopharmaceutical
- subject has role
- monoclonal antibody
via Wikidata · CC0
~4 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- Adverse effects
- Pharmacology
- Chemistry
- History
- References
Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, psoriatic arthritis, and hidradenitis suppurativa. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.
== Medical uses == Secukinumab is used to treat psoriasis, ankylosing spondylitis, psoriatic arthritis, and hidradenitis suppurativa. It is given by subcutaneous injection and is sold in a pre-filled syringe or autoinjector that can be used at home and as a lyophilized powder for use in hospitals and clinics. In October 2023, the FDA approved an intravenous variant of secukinumab.
Excerpted from Wikipedia’s “secukinumab” article, available under the CC BY-SA 4.0 licence.